|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: POLR2H |
Gene summary for POLR2H |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | POLR2H | Gene ID | 5437 |
| Gene name | RNA polymerase II, I and III subunit H | |
| Gene Alias | RPABC3 | |
| Cytomap | 3q27.1 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | P52434 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5437 | POLR2H | LZE2T | Human | Esophagus | ESCC | 4.73e-09 | 9.01e-01 | 0.082 |
| 5437 | POLR2H | LZE4T | Human | Esophagus | ESCC | 1.88e-22 | 8.09e-01 | 0.0811 |
| 5437 | POLR2H | LZE5T | Human | Esophagus | ESCC | 2.62e-02 | 6.63e-01 | 0.0514 |
| 5437 | POLR2H | LZE7T | Human | Esophagus | ESCC | 6.34e-15 | 1.04e+00 | 0.0667 |
| 5437 | POLR2H | LZE8T | Human | Esophagus | ESCC | 1.68e-13 | 6.23e-01 | 0.067 |
| 5437 | POLR2H | LZE20T | Human | Esophagus | ESCC | 3.48e-10 | 3.04e-01 | 0.0662 |
| 5437 | POLR2H | LZE22D1 | Human | Esophagus | HGIN | 1.12e-04 | 9.59e-02 | 0.0595 |
| 5437 | POLR2H | LZE22T | Human | Esophagus | ESCC | 4.95e-05 | 6.06e-01 | 0.068 |
| 5437 | POLR2H | LZE24T | Human | Esophagus | ESCC | 1.61e-25 | 9.09e-01 | 0.0596 |
| 5437 | POLR2H | LZE21T | Human | Esophagus | ESCC | 1.03e-14 | 1.20e+00 | 0.0655 |
| 5437 | POLR2H | LZE6T | Human | Esophagus | ESCC | 4.06e-17 | 1.04e+00 | 0.0845 |
| 5437 | POLR2H | P1T-E | Human | Esophagus | ESCC | 1.84e-13 | 8.44e-01 | 0.0875 |
| 5437 | POLR2H | P2T-E | Human | Esophagus | ESCC | 3.76e-90 | 1.78e+00 | 0.1177 |
| 5437 | POLR2H | P4T-E | Human | Esophagus | ESCC | 5.82e-72 | 2.31e+00 | 0.1323 |
| 5437 | POLR2H | P5T-E | Human | Esophagus | ESCC | 2.48e-64 | 1.28e+00 | 0.1327 |
| 5437 | POLR2H | P8T-E | Human | Esophagus | ESCC | 6.55e-52 | 1.12e+00 | 0.0889 |
| 5437 | POLR2H | P9T-E | Human | Esophagus | ESCC | 1.58e-50 | 1.26e+00 | 0.1131 |
| 5437 | POLR2H | P10T-E | Human | Esophagus | ESCC | 3.62e-95 | 1.67e+00 | 0.116 |
| 5437 | POLR2H | P11T-E | Human | Esophagus | ESCC | 2.18e-26 | 1.46e+00 | 0.1426 |
| 5437 | POLR2H | P12T-E | Human | Esophagus | ESCC | 3.52e-41 | 8.67e-01 | 0.1122 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0501630 | Esophagus | HGIN | Huntington disease | 129/1383 | 306/8465 | 6.81e-28 | 7.41e-26 | 5.88e-26 | 129 |
| hsa034205 | Esophagus | HGIN | Nucleotide excision repair | 29/1383 | 63/8465 | 2.96e-08 | 5.36e-07 | 4.26e-07 | 29 |
| hsa030205 | Esophagus | HGIN | RNA polymerase | 12/1383 | 34/8465 | 5.62e-03 | 3.99e-02 | 3.17e-02 | 12 |
| hsa05016113 | Esophagus | HGIN | Huntington disease | 129/1383 | 306/8465 | 6.81e-28 | 7.41e-26 | 5.88e-26 | 129 |
| hsa0342012 | Esophagus | HGIN | Nucleotide excision repair | 29/1383 | 63/8465 | 2.96e-08 | 5.36e-07 | 4.26e-07 | 29 |
| hsa0302012 | Esophagus | HGIN | RNA polymerase | 12/1383 | 34/8465 | 5.62e-03 | 3.99e-02 | 3.17e-02 | 12 |
| hsa05016210 | Esophagus | ESCC | Huntington disease | 226/4205 | 306/8465 | 1.38e-18 | 8.72e-17 | 4.46e-17 | 226 |
| hsa0342022 | Esophagus | ESCC | Nucleotide excision repair | 54/4205 | 63/8465 | 2.01e-09 | 2.17e-08 | 1.11e-08 | 54 |
| hsa0302021 | Esophagus | ESCC | RNA polymerase | 28/4205 | 34/8465 | 8.19e-05 | 3.35e-04 | 1.71e-04 | 28 |
| hsa046234 | Esophagus | ESCC | Cytosolic DNA-sensing pathway | 49/4205 | 75/8465 | 4.35e-03 | 1.12e-02 | 5.74e-03 | 49 |
| hsa0501638 | Esophagus | ESCC | Huntington disease | 226/4205 | 306/8465 | 1.38e-18 | 8.72e-17 | 4.46e-17 | 226 |
| hsa0342032 | Esophagus | ESCC | Nucleotide excision repair | 54/4205 | 63/8465 | 2.01e-09 | 2.17e-08 | 1.11e-08 | 54 |
| hsa0302031 | Esophagus | ESCC | RNA polymerase | 28/4205 | 34/8465 | 8.19e-05 | 3.35e-04 | 1.71e-04 | 28 |
| hsa0462311 | Esophagus | ESCC | Cytosolic DNA-sensing pathway | 49/4205 | 75/8465 | 4.35e-03 | 1.12e-02 | 5.74e-03 | 49 |
| hsa0501614 | Liver | Cirrhotic | Huntington disease | 172/2530 | 306/8465 | 1.65e-22 | 1.10e-20 | 6.77e-21 | 172 |
| hsa03420 | Liver | Cirrhotic | Nucleotide excision repair | 29/2530 | 63/8465 | 4.81e-03 | 1.74e-02 | 1.07e-02 | 29 |
| hsa0501615 | Liver | Cirrhotic | Huntington disease | 172/2530 | 306/8465 | 1.65e-22 | 1.10e-20 | 6.77e-21 | 172 |
| hsa034201 | Liver | Cirrhotic | Nucleotide excision repair | 29/2530 | 63/8465 | 4.81e-03 | 1.74e-02 | 1.07e-02 | 29 |
| hsa0501622 | Liver | HCC | Huntington disease | 219/4020 | 306/8465 | 3.06e-18 | 3.42e-16 | 1.90e-16 | 219 |
| hsa034202 | Liver | HCC | Nucleotide excision repair | 41/4020 | 63/8465 | 3.59e-03 | 1.12e-02 | 6.22e-03 | 41 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| POLR2H | SNV | Missense_Mutation | c.97G>A | p.Glu33Lys | p.E33K | P52434 | protein_coding | tolerated(0.13) | probably_damaging(0.985) | TCGA-A2-A0YH-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
| POLR2H | SNV | Missense_Mutation | c.169N>T | p.Arg57Trp | p.R57W | P52434 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| POLR2H | SNV | Missense_Mutation | c.55G>A | p.Gly19Ser | p.G19S | P52434 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-AA-3693-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| POLR2H | SNV | Missense_Mutation | c.208N>G | p.Leu70Val | p.L70V | P52434 | protein_coding | tolerated(0.33) | benign(0.11) | TCGA-D5-6532-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| POLR2H | SNV | Missense_Mutation | c.31N>A | p.Asp11Asn | p.D11N | P52434 | protein_coding | tolerated(0.27) | benign(0.046) | TCGA-DC-4745-01 | Colorectum | rectum adenocarcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | SD | |
| POLR2H | SNV | Missense_Mutation | novel | c.233N>T | p.Thr78Ile | p.T78I | P52434 | protein_coding | tolerated(0.09) | benign(0.042) | TCGA-EF-5831-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| POLR2H | SNV | Missense_Mutation | c.169N>T | p.Arg57Trp | p.R57W | P52434 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| POLR2H | SNV | Missense_Mutation | rs150492338 | c.409N>T | p.Arg137Cys | p.R137C | P52434 | protein_coding | deleterious(0) | possibly_damaging(0.685) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| POLR2H | SNV | Missense_Mutation | rs376240144 | c.332N>A | p.Arg111His | p.R111H | P52434 | protein_coding | tolerated(0.29) | benign(0) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| POLR2H | SNV | Missense_Mutation | novel | c.242G>A | p.Arg81Lys | p.R81K | P52434 | protein_coding | tolerated(0.24) | benign(0.001) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |